Today we at Eurofins Central Laboratory recognize a rare neurological disorder known as Moebius Syndrome.
This condition targets the muscles that control facial expression and eye movement, affecting individuals' ability to smile, frown, and raise their eyebrows. Moebius Syndrome also resonates to autism spectrum disorders due to impaired communication and social interaction.
According to the United States Library of Medicine, researchers estimate:
Moebius Syndrome affects 1 in 50,000 to 1 in 500,000 newborns each year.
Although the cause of this disease is unknown, it is speculated that environmental and genetic factors can provide key insight. Gene mutations PLXND1 and REV3L have recently been identified in individuals with Moebius Syndrome.
Today, relatable signs and symptoms, a detailed patient history, and thorough clinical evaluations are used to come to a diagnosis of Moebius Syndrome. There are no diagnostic tests to confirm a diagnosis, but there are specialized tests to rule out causes of facial paralysis.
At Eurofins Central Laboratory, a division of Eurofins BioPharma Services, we are dedicated to supporting our followers in the realm of neurological disorders such as Moebius Syndrome with our four standardized, wholly-owned global locations in the United States, Netherlands, Singapore, and China. We provide CAP/CLIA certified analytical services in both a GCP & GLP environment which allows us to combine thorough Safety/Efficacy analysis with Biomarker Services embedded within one laboratory, thereby introducing cost efficiencies into your study budget, and increasing specimen integrity by reducing unnecessary transport.